A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of PEGPH20 (PEGylated Recombinant Human Hyaluronidase) with Initial Dexamethasone Premedication Given Intravenously to Patients with Advanced Solid Tumors.

Trial Profile

A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of PEGPH20 (PEGylated Recombinant Human Hyaluronidase) with Initial Dexamethasone Premedication Given Intravenously to Patients with Advanced Solid Tumors.

Completed
Phase of Trial: Phase I

Latest Information Update: 26 Sep 2017

At a glance

  • Drugs Hyaluronidase (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Halozyme Therapeutics
  • Most Recent Events

    • 26 Sep 2017 Results published in the British Journal of Cancer.
    • 27 Jan 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 05 Apr 2013 Data will be presented at the American Association for Cancer Research Annual Meeting 2013, according to a Sarah Cannon Research Institute media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top